Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients

ABSTRACT: The variability and unpredictability of drug efficacy in ulcerative colitis (UC) patients, including tofacitinib, an oral JAK1 and JAK3 inhibitor, remains a perplexing reality. Here, we use single-cell RNA sequencing (scRNA-seq) analysis of intestinal cells from UC patients receiving tofacitinib to identify the cellular subsets and genes involved in the response and/or resistance to tofacitinib.

ORGANISM(S): Homo sapiens

PROVIDER: GSE253006 | GEO | 2025/05/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Analysis of rectal transcriptome in ulcerative colitis (UC) patients who received tofacitinib

Project description:The gold of this study is to identify genes that differentially expressed in rectum of ulcerative colitis patients who are responisve to tofacitinib compared with the patients who are refractory to the drug. This study may help to identify preditive markers to determine tofacitinib responders prior to the treatment.

2024-10-01 | GSE245890 | GEO

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment

Project description:The myeloma bone marrow microenvironment drives proliferation of malignant plasma cells and promotes resistance to therapy. Interleukin-6 (IL-6) and downstream JAK/STAT signaling are thought to be central components of these microenvironment-induced phenotypes. In a prior drug repurposing screen, we identified tofacitinib, a pan-JAK inhibitor FDA-approved for rheumatoid arthritis, as an agent that may reverse the tumor-stimulating effects of bone marrow mesenchymal stromal cells.Here, we validated both in vitro, in stromal-responsive human myeloma cell lines, and in vivo, in orthotopic disseminated murine xenograft models of myeloma, that tofacitinib showed both single-agent and combination therapeutic efficacy in myeloma models. Surprisingly, we found that ruxolitinib, an FDA-approved agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma effects. Combination with a novel irreversible JAK3-selective inhibitor also did not rescue ruxolitinib effects. RNA-seq and unbiased phosphoproteomics revealed that marrow stromal cells drive a JAK/STAT-mediated proliferative program in myeloma plasma cells, and tofacitinib reversed the large majority of these pro-growth signals. Taken together, our results suggest that tofacitinib specifically reverses the growth-promoting effects of the tumor microenvironment through blocking an IL-6-mediated signaling axis. As tofacitinib is already FDA-approved, these results can be rapidly translated into potential clinical benefits for myeloma patients.

2018-10-24 | PXD006581 | Pride

Analysis of rectal transcriptome in ulcerative colitis (UC) patients who received tofacitinib

Project description:Analysis of rectal transcriptome in ulcerative colitis (UC) patients who received tofacitinib

| PRJNA1030353 | ENA

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment

Project description:The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Interleukin-6 (IL-6) and downstream JAK/STAT signaling are thought to be central components of these microenvironment-induced phenotypes. In a prior drug repurposing screen, we identified tofacitinib, a pan-JAK inhibitor FDA-approved for rheumatoid arthritis, as an agent that may reverse the tumor-stimulating effects of bone marrow mesenchymal stromal cells. Here, we validated both in vitro, in stromal-responsive human myeloma cell lines, and in vivo, in orthotopic disseminated murine xenograft models of myeloma, that tofacitinib showed both single-agent and combination therapeutic efficacy in myeloma models. Surprisingly, we found that ruxolitinib, an FDA-approved agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma effects. Combination with a novel irreversible JAK3-selective inhibitor also did not enhance ruxolitinib effects. RNA-seq and unbiased phosphoproteomics revealed that marrow stromal cells stimulate a JAK/STAT-mediated proliferative program in myeloma plasma cells, and tofacitinib reversed the large majority of these pro-growth signals. Taken together, our results suggest that tofacitinib specifically reverses the growth-promoting effects of the tumor microenvironment through blocking an IL-6-mediated signaling axis. As tofacitinib is already FDA-approved, these results can be rapidly translated into potential clinical benefits for myeloma patients.

2017-05-26 | GSE99293 | GEO

Evaluation of tofacitinib in cutaneous sarcoidosis [scRNA-seq]

Project description:Sarcoidosis is a multisystem inflammatory disease and no molecularly targeted therapies exist. Here we evaluate the efficacy of tofacitinib (a JAK1/3 inhibitor) in an open-label trial of 10 patients with sarcoidosis and correlate clinical improvement with molecular parameters in blood and skin.

2022-03-30 | GSE169147 | GEO

IBD single cell data from colonic mucosa

Project description:Inflammatory bowel diseases (IBDs) including ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory diseases with increasing worldwide prevalence that show a perplexing heterogeneity in manifestations and response to treatment. We applied single cell RNA sequencing (scRNAseq) a to colonic tissue from a combined healthy, UC and CD cohort.

2023-06-07 | GSE214695 | GEO

Evaluation of tofacitinib in cutaneous sarcoidosis [Olink Explore 1536]

2022-03-30 | GSE169148 | GEO

Evaluation of tofacitinib in cutaneous sarcoidosis [bulk RNA-seq]

2022-03-30 | GSE169146 | GEO

Transcription profiling of human ulcerative colitis colonic mucosa to define an ulcerative colitis preinflammatory state

Project description:The samples are a part of a study aiming at diagnosing ulcerative colitis from genome-wide gene expression analysis of the colonic mucosa. Colonic mucosal samples were collected as endoscopic pinch biopsies from ulcerative colitis patients and from control subjects. Samples with and without macroscopic signs of inflammation were collected from the patients. Experiment Overall Design: The series contain eight UC samples with macroscopic signs of inflammation, 13 UC smaples without macroscopic signs of inflammation, five control subjects.

2008-06-20 | E-GEOD-9452 | biostudies-arrayexpress

Unravelling the mechanism of action of Tofacitinib on immune cell trafficking through IBD-associated microvasculature

Project description:In order to investigate the effect of tofacitinib on leukocyte trafficking through primary HIMEC from patients with UC, we designed a pilot experiment with the aim to establish the most efficient JAK inhibiting dose. For this purpose, we performed a dose-dependent experiment on UC-derived HIMEC, assessing Peripheral Blood Mononuclear Cells (PBMC) transmigration and using a range between 10 and 300 nM (10, 50, 100, 300 nM), according to the literature. More in detail, in a Transwell system (Figure 1), 500.000 PBMC, in 3 replicates, have been plated on confluent monolayers of untreated or Tofacitinib pre-treated (24 hours) UC-HIMEC at the various concentrations. After 18 hours of incubation transmigrated PBMC have been counted and their phenotype characterized by FACS. In order to avoid any direct effect of Tofacitinib on PBMC, the 18 hour- long incubation has been performed in the absence of the drug.

2021-12-09 | GSE165636 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data